The relationship between first and second trimester biochemical parameters used to screen down syndrome and intrahepatic cholestasis of pregnancy

Cuma Taşın1*, Nezaket Kadıoğlu2, Revan Sabri Çiftçi1, Hatun Çolak1, Hakan Aytan1

1 Dept Of Obstetrics And Gynecology, Mersin University Faculty Of Medicine, Mersin, TR
2 Dept Of Obstetrics And Gynaecology, Yüksek İhtisas University Faculty Of Medicine, Ankara, TR

* Corresponding Author: Cuma Taşın E-mail: cumatasin@gmail.com

ABSTRACT

Objective: To assess the role of first and second-trimester screening biomarkers pregnancy-associated plasma protein-A(PAPP-A), free beta-human chorionic gonadotropin(free ß-hCG), estriol, alpha-fetoprotein and total β-hCG in the early diagnosis of intrahepatic cholestasis of pregnancy (ICP).

Materials and Methods: Patients with ICP admitted to Mersin University Hospital for delivery between 2015 and 2019 and had first and second-trimester aneuploidy screening tests performed in the same facility were retrospectively assessed. Randomly 60 pregnant women without comorbid conditions during the same period were included as controls. Data regarding demographic characteristics, laboratory values including free ß-hCG and PAPP-A in first-trimester screening and total β-hCG, estriol and alpha-fetoprotein in second-trimester screening were compared.

Results: There were 46 eligible patients with ICP. In first trimester screening, it was found that PAPP-A MoM was significantly lower (0.89±0.55 vs. 1.94±0.73; p=0.035) while free ß-hCG MoM was significantly higher in ICP group when compared to controls (1.84±0.59 vs. 0.99±0.47; p=0.018). In second trimester screening, no significant difference was detected in aneuploidy markers between groups. For prediction of ICP development, first trimester free β-hCG >1.44 MoM was found to have a sensitivity of 50%, a specificity of 80% and positive and negative predictive values of 33% and 88.9% respectively. Similarly first trimester PAPP-A values <1.075 MoM was found to have 80% and 75% sensitivity and specificity with positive and negative predictive values of 75% and 44% respectively.

Conclusion: Low PAPP-A MoM value and elevated free ß-hCG in first trimester seem to be associated with ICP development.

Keywords: Alpha-fetoprotein (AFP), estriol, free beta-human chorionic gonadotropin (free ß-hCG), intrahepatic cholestasis of pregnancy, pregnancy-associated plasma protein-A (PAPP-A)

INTRODUCTION

The intrahepatic cholestasis of pregnancy (ICP) is a common hepatic disorder seen in 0.1% to 15.6% of pregnancies [1]. In ICP, there are elevated hepatic function tests and bile acids levels that result in itching of soles and palms. The itching is more commonly seen at late second trimester and third trimester [2]. The itching shows spontaneous recovery 5 to 6 weeks after delivery [3]. In patients with ICP, poor perinatal outcomes are more common than normal healthy pregnant women because of increased rates of gestational diabetes, pre-eclampsia, meconium in amniotic fluid and preterm delivery [4, 5]. Many physiological alterations occur in organs and the body during pregnancy [6]. The hormonal changes in pregnancy, genetics, and environmental factors affect biliary transport and secretion. Although the etiology of ICP hasn't been fully elucidated, above-mentioned factors have been implied in the etiopathogenesis of the disease [7]. The early diagnosis and treatment are important in the ICP. There are reports suggesting that parameters used in first-trimester screening tests (pregnancy-associated plasma protein A (PAPP-A) and free beta-human chorionic gonadotropin (free ß-hCG) can be used as early markers for ICP [8].
In our study, we investigated role of first and second trimester screening tests including PAPP-A, free β-hCG, estriol (E3), alpha-fetoprotein (AFP), and total β-hCG in the early diagnosis of ICP.

RESULTS

Overall, 46 eligible patients were included. Of the patients, 6 gave birth via vaginal route while 40 gave birth via abdominal route. Of patients with ICP, ursodeoxycholic acid therapy was given to 38 patients. No significant differences were detected between groups regarding mean age, gestational age at admission, fetal weight and umbilical artery pH values at birth (Table 1).

When laboratory values were assessed, it was found that ALP, ALT and AST were significantly higher in ICP group while there was no significant difference in GGT level between groups (Table 1).

In first trimester screening, it was found that PAPP-A MoM was significantly lower (0.89±0.55 vs. 1.94±0.73; p=0.035) while free β-hCG MoM was significantly higher in ICP group when compared to controls (1.84±0.59 vs. 0.99±0.47; p=0.018) (Table 1).

In second trimester screening, no significant difference was detected in aneuploidy markers between groups (Table 1).

The predictive abilities of first and second-trimester PAPP-A and free β-hCG MoM levels for the diagnosis of ICP were depicted in Figure 1 and table 2. Both markers were found to have significant predictive ability for the future development of ICP. First trimester free β-hCG >1.44 MoM was found to have a sensitivity of 50%, a specificity of 80% and positive and negative predictive values of 33% and 88.9% respectively. Similarly first trimester PAPP-A values <1.075 MoM was found to have 80% and 75% sensitivity and specificity respectively with positive and negative predictive values of 75% and 44% respectively (Table 2).

Table 1: Characteristics and mean laboratory values in patients with intrahepatic cholestasis of pregnancy and controls

|                      | Patients with intrahepatic cholestasis of pregnancy (n=46) | Controls (n=60) | P      |
|----------------------|-------------------------------------------------------------|-----------------|--------|
| Age (year)           | 27.1±5.4                                                     | 29.3±6.3        | 0.20   |
| Gestational week     | 32±5                                                        | 32±7            | 0.37   |
| Fetal weight (gram)  | 305±70                                                      | 2290±680        | 0.57   |
| GGT (IU/L)           | 19±12                                                       | 27±3±5          | 0.70   |
| ALP (IU/L)           | 208±73                                                      | 137±83          | 0.001* |
| ALT (IU/L)           | 178±146                                                     | 52±40           | 0.0001*|
| AST (IU/L)           | 119±49                                                      | 44±40           | 0.0001*|
| Bile acid (IU/L)     | 45±5.6                                                      | N/A             | N/A    |
| Dose of medication   | 675±38                                                      | N/A             | N/A    |
| Umbilical Artery Ph  | 7.32±0.05                                                   | 7.28±0.09       | 0.11   |
| PAPP-A (mom)         | 0.89±0.55                                                   | 1.94±0.73       | 0.035* |
| Free β-hCG (mom)     | 1.84±0.59                                                   | 0.99±0.47       | 0.018* |
| Estriol (mom)        | 1.12±0.19                                                   | 0.69±0.21       | 0.13   |
| β-hCG (mom)          | 1.14±0.39                                                   | 0.64±0.21       | 0.26   |
| AFP (mom)            | 0.95±0.01                                                   | 1.19±0.21       | 0.13   |

Student T test was employed. * p<0.05, ALT − ALT -serum alanine transaminase, AST − serum aspartat transaminase, GGT − γ-glutamyl transpeptidase, ALP − alkaline phosphatase, AFP − α-fetoprotein, hCG − human chorionic gonadotropin, MoM − multiple of the median, PAPP-A − pregnancy-associated plasma protein A, AFP-alfa fetu protein.

Medical Science and Discovery, 2021; 8(12):692-697
Intrahepatic cholestasis is the most common liver disease during pregnancy and is associated with adverse maternal and fetal outcomes. It is a diagnosis of exclusion, therefore, it is not always easy to diagnose the disease. Any marker that provide early diagnosis would result in prompt intervention and consequently decrease the adverse outcome risks. In the present study we assessed the roles of first and second trimester aneuploidy markers in the prediction of ICP development and showed that first trimester PAPP-A and free β-hCG MoM levels, but not second trimester markers, may have a comparable predictive potential for the subsequent ICP development throughout the pregnancy. The biochemical markers used for Down syndrome screening can predict poor maternal and fetal outcomes. It was shown that low PAPP-A level is associated with preeclampsia, gestational diabetes mellitus, preterm delivery, intrauterine growth retardation, preterm rupture of membranes and placental ablation [9-12]. A high PAPP-A value was suggested to be associated with a higher rate of meconium-stained amniotic fluid [13] First trimester low hCG levels are reported to be associated with increased risk for intrauterine growth restriction (IUGR), preterm birth, low birth weight (LBW) and low Apgar scores whereas high levels are related with a significantly decreased risk of preterm birth and GDM [14].

In the second trimester both low and high β-hCG levels were found to be associated with increased risk for spontaneous abortion, IUGR and preterm birth [14].

The relationship between these aneuploidy markers and the development of ICP has also been assessed in a few studies. Hancerlioglu et al. reported low PAPP-A and high free β-hCG levels were associated with obstetric cholestasis [8]. They included 35 ICP patients and found the mean PAPP-A and free beta hCG MoM levels as 0.76 ± 0.31 and 1.2 ± 0.79 respectively. Contrary to this study, another study from the same country could not find an association between low first trimester PAPP-A levels and ICP [15]. Destici et al. reported median PAPP-A MoM levels as 0.93 in ICP group. In the present study the median first trimester PAPP-A levels were 0.89 which was significantly lower in ICP patients. In ROC analysis, the area under the curve was found to be 0.88, and values >0.8 is considered to be a strong predictor of clinical sensitivity or specificity (16). In their study, Tayyar et al. found PAPP-A <0.93 MoM as a cut-off value for prediction of ICP with 73.8% sensitivity and 56.3 specificities (95% CI, AUC± SE: 0.663 ±0.042). [17]; however, different than our results, they did not find free hCG to be associated with ICP. They also could not find any relationship between second-trimester markers, including Inhibin A, with subsequent ICP.

### DISCUSSION

Table 2: Likelihood of detecting intrahepatic cholestasis of pregnancy according to free β-hCG cut-off value

| Free β-hCG (MoM) Cut Off >1,44 | AUC  | Sensitivity | Specificity | PPV  | NPV  | P     |
|-------------------------------|------|-------------|-------------|------|------|-------|
| Free β-hCG (MoM) Cut Off <1,075 | 0.88 | 80%         | 75%         | 44%  | 93.7%| 0.01* |

*p<0.05, MoM – multiple of the median, Free Beta hCG-free human chorionic gonadotropin AUC – area under the receiver operating curve, MoM – multiple of the median, NPV- negative predictive value, PPV- positive predictive value.

![Figure 1](image.png)

**Figure 1**: ROC curves for free β-hCG and PAPP-A in intrahepatic cholestasis of pregnancy

**Table 2**: Likelihood of detecting intrahepatic cholestasis of pregnancy according to free β-hCG cut-off value

![Table 2](image.png)

In the second trimester both low and high β-hCG levels were found to be associated with increased risk for spontaneous abortion, IUGR and preterm birth [14].

The relationship between these aneuploidy markers and the development of ICP has also been assessed in a few studies. Hancerlioglu et al. reported low PAPP-A and high free β-hCG levels were associated with obstetric cholestasis [8]. They included 35 ICP patients and found the mean PAPP-A and free beta hCG MoM levels as 0.76 ± 0.31 and 1.2 ± 0.79 respectively. Contrary to this study, another study from the same country could not find an association between low first trimester PAPP-A levels and ICP [15]. Destici et al. reported median PAPP-A MoM levels as 0.93 in ICP group. In the present study the median first trimester PAPP-A levels were 0.89 which was significantly lower in ICP patients. In ROC analysis, the area under the curve was found to be 0.88, and values >0.8 is considered to be a strong predictor of clinical sensitivity or specificity (16). In their study, Tayyar et al. found PAPP-A <0.93 MoM as a cut-off value for prediction of ICP with 73.8% sensitivity and 56.3 specificities (95% CI, AUC± SE: 0.663 ±0.042). [17]; however, different than our results, they did not find free hCG to be associated with ICP. They also could not find any relationship between second-trimester markers, including Inhibin A, with subsequent ICP.
In the present study PAPP-A 1.075 MoM was found as a cut-off value with substantial sensitivity, specificity, positive and negative predictive values. Therefore low PAPP-A MoM values seem to have a predictive potential for subsequent ICP.

PAPP-A is a glycoprotein secreted from the extravillous trophoblasts of the placenta [18] and it cleaves insulin-like growth factor binding protein (IGFBP)-4 and -5 [19]. By this way it modulates the activity of insulin-like growth factor (IGF)-1 and -2 [20]. Low levels of PAPP-A results in decreased IGF levels due to decreased cleavage of the binding protein. In addition PAPP-A plays a role in the autocrine and paracrine control of trophoblast invasion of the decidua [21] and any change during this period may have a negative effect continuation of pregnancy.

The failure in invasion (due to IGF effect) increases the risk for intrauterine growth retardation, pregnancy-related hypertension, and intrauterine death in advancing periods of pregnancy. In some studies, it was found that low PAPP-A levels reduced blood IGF level. The decreased IGF levels in pregnancy results in poor pregnancy outcomes such as preterm birth, preeclampsia, gestational diabetes mellitus, and intrauterine fetal death [22, 23].

In a study on cholestatic rats, it was found that IGF therapy increased flow of bile acids and improved clinical presentation [24,25], concluding that there is an association between decreased IGF level and biliary flow. In the study, it was found that IGF is important for bile acid homeostasis and secretion and that endogenous and exogenous IGF decreased blood bile acid. The reduction in PAPP-A levels in early pregnancy can lead decrease in protease effect on IGF-4 and IGF-5; thus, ICP development in advancing weeks of pregnancy as a result of decreased IGF. Contrary to first trimester, high levels of third trimester PAPP-A levels have been observed in ICP patients [9].

Therefore obstetric conditions in which there is inadequate trophoblastic invasion in the first trimester would be associated with a low PAPP-A level, whereas hypoperfusion-related stimulation of the production of placental proteins in the second and third trimesters would be associated with a high PAPP-A level [9].

By initiation of pregnancy, trophoblastic cells begin to secrete glycoprotein β-hCG. The increased free β-hCG level in fetal and maternal blood has 80% similarity with luteinizing hormone (LH). The increased free β-hCG in fetal and maternal blood binds to LH/βhCG receptors, inducing steroidogenesis. The induced steroidogenesis results in formation of estrogen and progesterone metabolites. The increased estrogen and progesterone metabolites due to elevated free β-hCG inhibit bile acid transportation in pregnant women. The increased blood bile acid levels due to failure in excretion lead increase in fetal and/or maternal toxicity and complications [7, 26, 27].

As placental hormone levels are increased by advancing gestational age, ICP is most frequently seen in third trimester. In multiple pregnancies, ICP is more common since placental hormones were higher [28]. In a study by Hancerlioglu et al., a relationship was found between high levels of β-hCG and ICP [8]. However, no such relationship was found in some studies [29].

In our study, it was found that free β-hCG level in first trimester was significantly higher in ICP group when compared to controls. In ROC analysis, a relatively higher AUC value was found and a cut-off value of 1.44 MoM was calculated for free β-hCG. It was also found that the cut-off value can predict ICP by the sensitivity of 80% and specificity of 50%, indicating that first trimester free β-hCG level can be a potential marker for ICP.

Alpha-fetoprotein (AFP) is a glycoprotein secreted from fetal liver and yolk sac. It is a parameter of second trimester testing used for Down syndrome screening between gestational weeks 16 and 20. There are reports suggesting that low AFP MoM values are associated with gestational DM while high AFP and β-hCG MoM values were associated with preeclampsia [30, 31].

In previous studies, no relationship was found between the second-trimester screening test and ICP [17, 32, 33]. In a study by Yuan et al., it was concluded that the increased maternal AFP and estriol (E3) levels lead to an increase in risk for ICP in the third trimester [34]. In the study, it was also found that placental anomalies such as placental previa and placental abruption were more common among patients with elevated AFP. The authors concluded that serum AFP level is increased in women with placental dysfunction; as a result, ICP can be seen more commonly in third trimester. In our study, no significant difference was found in AFP between ICP and control groups in agreement with literature.

In previous studies, AFP was more frequently seen in patients with impaired estrogen metabolism [35]. It was found that serum bile acids were increased in non-pregnant women using oral contraceptives with high estrogen and progesterone content [36]. In an in vitro study, it was found that progesterone metabolites, not progesterone itself, impaired bile acid transport [27].

The increased β-hCG level during pregnancy leads to an elevation in progesterone and its metabolite E3. The elevated E3 levels impair bile acid transport, increasing the risk for ICP. In a study by Raty et al. it was concluded that elevated β-hCG level is associated with ICP [29]. In two distinct study by Eloranta et al. and Raty et al., no relationship was detected maternal AFP and β-hCG levels and ICP [29, 33]. However, in the study by Raty et al., β-hCG levels were increased in the ICP group but did not reach statistical significance. In a study by Leslie et al., no significant difference was found in E3 level between ICP and control groups [37].

In our study, AFP levels in ICP groups were comparable with controls. However, both β-hCG and E3 levels were higher in ICP group than controls, but the difference did not reach statistical significance. The elevated E3 and β-hCG levels alone may not result in cholestasis. However, genetic sensitivity or environmental factors can lead ICP in patients with similar E3 and β-hCG levels.

Although GGT was found to be high in patients with ICP in some previous studies [12, 38] GGT levels were normal in patients with ICP in many studies in agreement with our results [32]. In patients with ICP, the extent of ALT increase was higher than AST [38, 39].
In our study, it was also found that ALT increased more than AST. Since ALP is mainly released from placenta, the use in ICP diagnosis is limited.

Our study is one of the rare studies that evaluated first and second-trimester biochemical markers together in patients with ICP. In our study, the diagnosis and treatment were conducted by the same healthcare providers in a single-center. Major limitations are retrospective design and small sample size. In addition, as it is the case in the studies using biochemical parameters, the values obtained are dependent to study population, laboratory and analyzer used. Thus, it will be appropriate to take these factors into consideration.

CONCLUSION

In conclusion, it was found that low PAPP-A MoM value, one of the Down syndrome screening tests in first trimester, and elevated free ß-hCG were associated with ICP development. Although other biochemical parameters were found to be higher in ICP group, no relationship with ICP was found. The early recognition of ICP is important as perinatal complications are more common in patients with ICP. ICP development can be predicted by low PAPP-A and high free ß-hCG MoM values in the first trimester. If women are already being screened for Down syndrome using the first-trimester aneuploidy test markers, which is routinely performed, the same markers can be employed to screen for ICP, offering a simple and low-cost opportunity to identify groups at high risk of developing this disorder. There is a need for prospective studies with a larger sample size for introduction to routine practice.

Author Contributions: CT, NK, RSÇ, HC, HA: Concept, Data collection and/or processing, Analysis and/or interpretation, Literature review. CT: Writing, Revision

Financial & competing interests’ disclosure: The authors have no relevant affiliations or financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Conflict of interest: The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. This research did not receive and specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Ethical approval: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by Local Ethical Committee.

REFERENCES

1. Kulhan M, Kulhan NG, Nayki U, et al. Intrahepatic cholestasis of pregnancy and fetal outcomes. Mini review. Arch Med Sci Civil Dis 2017; 2: e85-6.
2. Williamson C, Geenes V. Intrahepatic cholestasis of pregnancy. Obstet Gynecol 2014; 124: 120-33.
3. Ozkan S, Ceylan Y, Ozkan OV, et al. Review of a challenging clinical issue: intrahepatic cholestasis of pregnancy. World J Gastroenterol 2015; 21: 7134-41
4. Tayyar A, Temel Yuksel I, et al. Maternal copeptin levels in intrahepatic cholestasis of pregnancy. J Matern Neonatal Med 2017 Jun 14; 1–5.
5. Geenes V, Chappell LC, Seed PT, et al. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study. Hepatology 2014; 59: 1482-91.
6. Karahmet E, Ay Gongor ANC, Topaloglu N, et al. Revalence of psychiatric disorders during pregnancy and their effect on birth weight. Arch Med Sci Civil Dis 2016; 1: e24-9.
7. Arrese M, Macias RIR, Briz O, et al. Molecular pathogenesis of intrahepatic cholestasis of pregnancy. Expert Rev Mol Med 2008; 10: e9.
8. Hancerliogullari N, Aktulay A, Engin-Ustun Y, et al. Pregnancy-associated plasma protein a levels are decreased in obstetric cholestasis. Clin Exp Obstet Gynecol 2015;42: 617-8.
9. Kang JH, Farina A, Park JH, et al. Down syndrome biochemical markers and screening for preeclampsia at first and second trimester: correlation with the week of onset and the severity. Prenat Diagn 2008; 28: 704-9.
10. Gutj P, Wender-Ożegowska E, Brżert J. Maternal lipids associated with large-for-gestational-age birth weight in women with type I diabetes: results from a prospective single center study. Arch Med Sci 2017; 13: 753-9.
11. Goetzinger KR, Cahill AG, Macones GA, et al. Association of first-trimester low PAPP-A levels with preterm birth. Prenat Diagn 2010; 30: 309-13
12. Blumenfeld YJ, Baer RJ, Druzin ML, et al. Association between maternal characteristics, abnormal serum aneuploidy analytes, and placental abruption. Am J Obstet Gynecol. 2014; 211: 144.e1–144.e9, Perinatal Journal 2014;22(3):142-146, Turk J Obstet Gynecol, 2020 Mar; 17(1): 40-45.
13. AJOG. The association between first-trimester levels of PAPP-A and perinatal complications , volume 191,Issue 6, Suplement , S78, December 01, 2004.
14. Sirilkunai P, Wanapirak C, Sirichotiyakul S, et al. Associations between maternal serum free beta human chorionic gonadotropin (ß-hCG) levels and adverse pregnancy outcomes. J Obstet Gynaecol. 2016;36(2):178-82.
15. Aksan Desteli G, Sahin-Uysal N, Cok T, et al. First trimester maternal serum PAPP-A levels and associated pregnancy complications in intrahepatic cholestasis of pregnancy. Clin Exp Obstet Gynecol. 2016;43(5):673-677.
16. Akbeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr 2007; 6:644-647
17. Tayyar AT, Tayyar A, Atakul T, Tayyla , et al. Could first- and second-trimester biochemical markers for down syndrome have a role in predicting intrahepatic cholestasis of pregnancy? Arch Med Sci. 2018;14(4):846–50.
18. Handscluh K, Guibourdenche J, Guesnon M, et al. Modulation of PAPP-A expression by PPARGamma in human first trimester trophoblast. Placenta 2006; 27 Suppl A:S127-34.
19. Bowman CJ, Streck RD, Chapin RE. Maternal-placental insulin-like growth factor (IGF) signaling and its importance to normal embryo-fetal development. Birth Defects Res B Dev Reprod Toxicol 2010; 89: 339-49.
20. Clemmons DR. 1998. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol 140: 19–24
21. Irwin JC, Suen LF, Martina NA, et al. Role of the IGF system in trophoblast invasion and pre-eclampsia. Hum Reprod 1999;14: 90–96
22. Chelchowska M, Gajewska J, Mazur J, et al. Serum pregnancy-associated plasma protein A levels in the first, second and third trimester of pregnancy: relation to newborn anthropometric parameters and maternal tobacco smoking. Arch Med Sci 2016; 12: 1256-62

23. Gagnon A, Wilson RD, Audibert F, et al. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can 2008; 30: 918-49

24. Kawamura I, Takeshita S, Fushimi M, et al. Stimulation of choleresis by insulin-like growth factor-I in rats. Endocrinology 2000; 147: 249-55.

25. Mahushi M, Kawamura I, Fushimi M, et al. Choleretic actions of insulin like growth factor I, prednisolone, and ursodeoxycholic acid in rats. Dig Dis Sci 2003; 48: 1398-405.

26. Hagenbuch B, Dawson P. The sodium bile salt cotransport family SLC10. Pfugers Arch 2004; 447: 566-70.

27. Vallejo M, Briz O, Serrano MA, et al. Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy. J Hepatol 2006; 44:1150-7.

28. Glantz A, Reilly SJ, Benthin L, et al. Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology 2008; 47: 544-51.

29. Raty R, Aantila L, Virtanen A, et al. Maternal midtrimester free beta-HCG and AFP serum levels in spontaneous singleton pregnancies complicated by gestational diabetes mellitus, pregnancy-induced hypertension or obstetric cholestasis. Prenat Diagn 2003; 23: 1045-8.

30. Türkçapar F, Engin-Ustün Y, Simsek OY, et al. First and second trimester biochemical markers in familial Mediterranean fever. Eur Rev Med Pharmacol Sci. 2013;17(13):1820–3.

31. Cohen JL, Smilen KE, Bianco AT, et al. Predictive value of combined serum biomarkers for adverse pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol. 2014;181:89–94.

32. Türkmen GG, Timur H, Yilmaz Z, et al. Effect of intrahepatic cholestasis of pregnancy on maternal serum screening tests. J Neonatal-Perinatal Med.2016;9(4):411–5

33. Eloranta ML, Heinonen S, Kirkinen P. Intrahepatic cholestasis of pregnancy has no effect on maternal serum second trimester alpha-fetoprotein and hCG. Acta Obstet Gynecol Scand. 2000;79(7):548–52

34. Yuan X, Long W, Liu J, et al. Associations of serum markers screening for Down’s syndrome with pregnancy outcomes: a Chinese retrospective cohort study. Clin Chim Acta. 2019;489:130–5.

35. Reyes H, Ribaltu J, González MC, et al. Sulfobromophthalein clearance tests before and after ethinyl estradiol administration, in women and men with familial history of intrahepatic cholestasis of pregnancy. Gastroenterology 1981; 81: 226-231.

36. Barth A, Klinger G, Rost M. Influence of ethinyloestradiol propansulphonate on serum bile acids in healthy volunteers. Exp Toxicol Pathol 2003; 54: 381-386.

37. Leslie KK, Reznikov L, Simon FR, et al. Estrogens in intrahepatic cholestasis of pregnancy. Obstet Gynecol. 2000;95(3):372–6.

38. Milkiewicz P, Gallagher R, Chambers J, et al. Obstetric cholestasis with elevated gamma glutamyl transpeptidase: incidence, presentation and treatment. J Gastroenterol Hepatol 2003; 18: 1283-1286

39. Fisk NM, Bye WB, Storey GN. Maternal features of obstetric cholestasis: 20 years experience at King George V Hospital. Aust N Z J Obstet Gynaecol 1988; 28: 172-176